Class 2 recall-Levothyroxine 12.5mcg tablets Teva

Reason: “Teva UK Limited is recalling the above batch of Levothyroxine 12.5mcg Tablets in response to a lower than required assay result discovered during routine stability testing.”

MHRA drug alert date  02 March 2023

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-teva-uk-limited-levothyroxine-12-dot-5mcg-tablets-el-23-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=16a65f83-bc8f-4111-ab4d-5bbfef5ce896&utm_content=immediately

MHRA ref: MDR 226-02/23

Further Information

For any Levothyroxine stock enquiries please contact the Teva UK Limited Customer Solutions team on 0800 590 502.

For more information or medical enquiries, please contact Teva UK Limited by phone on 020 7540 7117 or by email to medinfo@tevauk.com

To report an adverse drug event to Teva UK Limited, please call 020 7540 7337, email uk.safety@tevauk.com or complete the online form at www.tevauk.com/Reporting-side-effects.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.